Dementia care report should be ‘catalyst for change,’ committee says … Pain perception may be early disease marker in Alzheimer’s gene carriers … Nursing home first-dose vaccination data released...
Drug that targets Alzheimer’s inflammation approved for trial by FDA
By
Alicia Lasek
Feb 09, 2021
An experimental drug meant to treat the “type 3 diabetes” that some scientists believe triggers Alzheimer’s has been approved for a late-stage clinical trial.
Clinical briefs for Monday, Feb. 1
By
Alicia Lasek
Feb 01, 2021
Advocates make fresh plea for prioritizing independent living in COVID vaccination clinics … Eli Lilly to test its approved antibody therapy against new COVID variants … FDA extends review for Biogen’s...
Surgery may accelerate Alzheimer’s in at-risk patients, scientists contend
By
Alicia Lasek
Jan 22, 2021
Memory test scores were significantly worse nine months after surgery in study participants who had markers of Alzheimer’s brain plaques, but no sign of dementia before surgery.
Nearly half of Alzheimer’s cases are mild, supporting a focus on early intervention
By
Alicia Lasek
Jan 14, 2021
The great prevalence of mild disease underscores the need for interventions that may slow decline or prevent progression in dementia, researchers contend.
Alzheimer’s drug slows mental, functional decline in Eli Lilly trial
By
Alicia Lasek
Jan 12, 2021
Participants who took donanemab for 76 weeks showed 32% slower decline in thinking and daily function compared with those in a placebo group.
New evidence pinpoints health clusters that raise dementia risk
By
Alicia Lasek
Jan 07, 2021
Older adults with diagnoses of neuropsychiatric and cardiovascular multimorbidity had the highest likelihood of developing dementia over 12 years, investigators report.
Exercise may keep mild cognitive impairment from advancing to dementia
By
Alicia Lasek
Nov 13, 2020
Study participants who began a weekly exercise routine after diagnosis with MCI had an 11% lower risk of progressing to Alzheimer’s when compared with people who did not exercise at all, a new study...
FDA advisers vote ‘no’ on drug that may slow Alzheimer’s progression
By
Alicia Lasek
Nov 09, 2020
If approved by the FDA, aducanumab would be the first-ever drug marketed to slow progression of the brain-wasting disease, according to its developer. But an advisory committee was unconvinced of the drug’s...
Alzheimer’s drug gets FDA support ahead of Friday vote on approval
By
Alicia Lasek
Nov 05, 2020
Documents released on Wednesday show that the agency’s staff members already are enthusiastic about the drug’s prospects. If approved, aducanumab could be the first drug on the market to slow Alzheimer’s...